Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2025.12.011
Whitney W. Stevens MD, PhD , Michael E. Wechsler MD , Tara F. Carr MD
The development, introduction, and widespread use of type 2–targeting biologics for respiratory disease has been of dramatic and unprecedented benefit to patients, improving disease control, reducing morbidity, and allowing for avoidance of more toxic therapies such as reliance on chronic systemic corticosteroids. Developed to treat more severe forms of asthma, the available biologics—benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, and tezepelumab—have been successfully applied to treat other diseases of the upper and lower airways. Indeed, multiple different biologics are now approved by the Food and Drug Administration for each general clinical indication: severe asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyposis. Clinically, the selection of a type 2–targeting biologic for respiratory disease starts with the confirmation of a specific diagnosis, assessment of responsiveness to previous medical (and surgical) therapies, and determination whether underlying type 2 inflammation is present. Other critical considerations include route of administration, accessibility, insurance coverage, and patient preference. In some cases, there may be only 1 biologic available for a patient. However, as often is the case, patients may indeed qualify for, or potentially benefit from, more than 1 treatment. Selecting the right treatment—that which is most effective—can be a challenge. In this review, we provide practical and evidence-based recommendations about selecting a type 2 biologic across the spectrum of respiratory diseases.
{"title":"Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease","authors":"Whitney W. Stevens MD, PhD , Michael E. Wechsler MD , Tara F. Carr MD","doi":"10.1016/j.jaip.2025.12.011","DOIUrl":"10.1016/j.jaip.2025.12.011","url":null,"abstract":"<div><div>The development, introduction, and widespread use of type 2–targeting biologics for respiratory disease has been of dramatic and unprecedented benefit to patients, improving disease control, reducing morbidity, and allowing for avoidance of more toxic therapies such as reliance on chronic systemic corticosteroids. Developed to treat more severe forms of asthma, the available biologics—benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, and tezepelumab—have been successfully applied to treat other diseases of the upper and lower airways. Indeed, multiple different biologics are now approved by the Food and Drug Administration for each general clinical indication: severe asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyposis. Clinically, the selection of a type 2–targeting biologic for respiratory disease starts with the confirmation of a specific diagnosis, assessment of responsiveness to previous medical (and surgical) therapies, and determination whether underlying type 2 inflammation is present. Other critical considerations include route of administration, accessibility, insurance coverage, and patient preference. In some cases, there may be only 1 biologic available for a patient. However, as often is the case, patients may indeed qualify for, or potentially benefit from, more than 1 treatment. Selecting the right treatment—that which is most effective—can be a challenge. In this review, we provide practical and evidence-based recommendations about selecting a type 2 biologic across the spectrum of respiratory diseases.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Pages 385-394"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145806266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2025.12.009
Yifei Cao MM , Yunhui Zhang PhD
{"title":"Menopause and Asthma Unlinked? It’s More Complicated","authors":"Yifei Cao MM , Yunhui Zhang PhD","doi":"10.1016/j.jaip.2025.12.009","DOIUrl":"10.1016/j.jaip.2025.12.009","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Pages 535-536"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2026.01.007
{"title":"Updates on the Current and Evolving Treatment for Hereditary Angioedema","authors":"","doi":"10.1016/j.jaip.2026.01.007","DOIUrl":"10.1016/j.jaip.2026.01.007","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Page 384"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2026.01.024
Simonne L Horwitz, Lianne Soller, Victoria E Cook, Scott B Cameron, Joanne Yeung, Sandeep Kapur, Mary McHenry, Edmond S Chan, Raymond Mak, Gregory A Rex, Tiffany Wong, Stephanie C Erdle
Clinical implications: In a real-world setting, 81.4% of preschoolers who received cashew and/or walnut OIT successfully tolerated a 4000mg follow-up oral food challenge, enabling dietary liberalization. Real-world cashew and walnut OIT should be considered as an alternative to avoidance in preschoolers.
{"title":"Real-World Effectiveness Analysis of Preschool Cashew and Walnut Oral Immunotherapy.","authors":"Simonne L Horwitz, Lianne Soller, Victoria E Cook, Scott B Cameron, Joanne Yeung, Sandeep Kapur, Mary McHenry, Edmond S Chan, Raymond Mak, Gregory A Rex, Tiffany Wong, Stephanie C Erdle","doi":"10.1016/j.jaip.2026.01.024","DOIUrl":"https://doi.org/10.1016/j.jaip.2026.01.024","url":null,"abstract":"<p><strong>Clinical implications: </strong>In a real-world setting, 81.4% of preschoolers who received cashew and/or walnut OIT successfully tolerated a 4000mg follow-up oral food challenge, enabling dietary liberalization. Real-world cashew and walnut OIT should be considered as an alternative to avoidance in preschoolers.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The optimal oral immunotherapy (OIT) protocol following low-dose desensitization remains unclear.
Objective: To compare the efficacy and safety of fixed low-dose versus escalation to medium dose for severe cow's milk allergy.
Methods: This study included children who had a positive oral food challenge (OFC) to 3 mL of milk before initiating OIT, had continued low-dose OIT targeting 3 mL for a minimum of 1 year, and subsequently failed OFC with 25 mL. They were randomized (32 children each) into "fixed-dose group; 3-mL target (99-mg protein)" or "dose-escalation group; 25-mL target (825-mg protein)." Short-term unresponsiveness to 25 mL was assessed using the OFC at 1 and 2 years after the 2-week avoidance.
Results: The fixed-dose group versus the dose-escalation group had the following characteristics, respectively: median age (9.2 vs 9.1 years), history of anaphylaxis (94% vs 100%), milk-specific IgE level (19.9 vs 27.0 kUA/L), and period from OIT initiation (2.0 vs 1.8 years). The rates of achieving 25 mL short-term unresponsiveness were 31% and 28% at 1 year and 47% and 44% at 2 years, respectively (P > .99). The total symptom frequency per OIT dose was 0.9% versus 3.8% in the first year, and 0.8% versus 2.0% in the second year (P < .001), and anaphylaxis was 0.01% versus 0.06% in the first year. Milk-, casein-, α-lactalbumin-, and β-lactoglobulin-specific IgE levels decreased from baseline at 2 years in both groups (P < .001).
Conclusions: The fixed low-dose OIT protocol following low-dose desensitization provides comparable efficacy and improved safety compared with dose escalation.
背景：低剂量脱敏后的最佳口服免疫疗法（OIT）方案尚不清楚。目的：比较固定低剂量与递增至中剂量治疗严重牛奶过敏的疗效和安全性。方法：本研究纳入了在开始OIT前对3ml牛奶口服食物刺激（OFC）呈阳性，持续低剂量OIT (3ml)≥1年，随后口服食物刺激（25ml）失败的儿童。他们随机分为“固定剂量组”（每组32名儿童）；3 mL靶（99 mg蛋白）”或“剂量递增组”；25ml靶蛋白（825mg蛋白）”。在回避2周后的1年和2年，使用OFC评估对25 mL的短期无反应性（STU）。结果：固定剂量组与剂量增加组分别具有以下特征：中位年龄（9.2 vs 9.1岁）、过敏史（94% vs 100%）、牛奶特异性IgE水平（19.9 vs 27.0 kUA/L）和从OIT开始的时间（2.0 vs 1.8年）。1年和2年达到25 mL STU的比率分别为31%和28%和47%和44% （p < 0.05）。第一年每次OIT剂量的总症状频率为0.9%对3.8%，第二年为0.8%对2.0% (p < 0.001)，第一年过敏反应为0.01%对0.06%。两组2年时，乳蛋白、酪蛋白、α-乳蛋白和β-乳球蛋白特异性IgE水平均较基线下降（p < 0.001）。结论：与剂量递增相比，低剂量脱敏后的固定低剂量OIT方案具有相当的疗效和更高的安全性。
{"title":"Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose.","authors":"Ken-Ichi Nagakura, Kyohei Takahashi, Yoko Miura, Kaito Goto, Akira Kawai, Naoko Fusayasu, Kiyotake Ogura, Sakura Sato, Motohiro Ebisawa, Noriyuki Yanagida","doi":"10.1016/j.jaip.2026.01.025","DOIUrl":"10.1016/j.jaip.2026.01.025","url":null,"abstract":"<p><strong>Background: </strong>The optimal oral immunotherapy (OIT) protocol following low-dose desensitization remains unclear.</p><p><strong>Objective: </strong>To compare the efficacy and safety of fixed low-dose versus escalation to medium dose for severe cow's milk allergy.</p><p><strong>Methods: </strong>This study included children who had a positive oral food challenge (OFC) to 3 mL of milk before initiating OIT, had continued low-dose OIT targeting 3 mL for a minimum of 1 year, and subsequently failed OFC with 25 mL. They were randomized (32 children each) into \"fixed-dose group; 3-mL target (99-mg protein)\" or \"dose-escalation group; 25-mL target (825-mg protein).\" Short-term unresponsiveness to 25 mL was assessed using the OFC at 1 and 2 years after the 2-week avoidance.</p><p><strong>Results: </strong>The fixed-dose group versus the dose-escalation group had the following characteristics, respectively: median age (9.2 vs 9.1 years), history of anaphylaxis (94% vs 100%), milk-specific IgE level (19.9 vs 27.0 kU<sub>A</sub>/L), and period from OIT initiation (2.0 vs 1.8 years). The rates of achieving 25 mL short-term unresponsiveness were 31% and 28% at 1 year and 47% and 44% at 2 years, respectively (P > .99). The total symptom frequency per OIT dose was 0.9% versus 3.8% in the first year, and 0.8% versus 2.0% in the second year (P < .001), and anaphylaxis was 0.01% versus 0.06% in the first year. Milk-, casein-, α-lactalbumin-, and β-lactoglobulin-specific IgE levels decreased from baseline at 2 years in both groups (P < .001).</p><p><strong>Conclusions: </strong>The fixed low-dose OIT protocol following low-dose desensitization provides comparable efficacy and improved safety compared with dose escalation.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2025.11.005
Laurence E. Ruane BSc , Paul Leong FRACP, PhD , Garun S. Hamilton FRACP, PhD , Emil S. Walsted MD, PhD , Joy Lee FRACP, PhD , Eve Denton FRACP, PhD , Elaine Yap MBChB, FRACP , Åse J. Rogde MD , Alice Crawford MBBS, FRACP , Paul A. Finlay DipAs , Martin I. MacDonald FRACP, PhD , John D. Brannan PhD , Kathryn Prior BSc, MBBS , Andrej A. Petrov MD , James H. Hull FRACP, PhD , Sally E. Wenzel MD , Peter G. Gibson FRACP, PhD , Philip G. Bardin FRACP, PhD
{"title":"Poor diagnostic performance of flow volume loops for detection of inducible laryngeal obstruction/vocal cord dysfunction","authors":"Laurence E. Ruane BSc , Paul Leong FRACP, PhD , Garun S. Hamilton FRACP, PhD , Emil S. Walsted MD, PhD , Joy Lee FRACP, PhD , Eve Denton FRACP, PhD , Elaine Yap MBChB, FRACP , Åse J. Rogde MD , Alice Crawford MBBS, FRACP , Paul A. Finlay DipAs , Martin I. MacDonald FRACP, PhD , John D. Brannan PhD , Kathryn Prior BSc, MBBS , Andrej A. Petrov MD , James H. Hull FRACP, PhD , Sally E. Wenzel MD , Peter G. Gibson FRACP, PhD , Philip G. Bardin FRACP, PhD","doi":"10.1016/j.jaip.2025.11.005","DOIUrl":"10.1016/j.jaip.2025.11.005","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Pages 531-533.e1"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2025.10.032
Eugenio De Corso PhD , Claudio Montuori MD , Ernesto Pasquini MD , Ignazio La Mantia PhD , Angelo Ghidini PhD , Carlotta Pipolo PhD , Massimiliano Garzaro MD , Giancarlo Ottaviano PhD , Veronica Seccia MD , Andrea Ciofalo MD , Sara Torretta MD , Elena Cantone PhD , Giulia Danè MD , Fabio Pagella MD , Daniela Lucidi MD , Gian Luca Fadda MD , Alice Mannocci PhD , Carlo Cavaliere PhD , Giulio Pagliuca PhD , Frank Rikki Mauritz Canevari MD , Riccardo Bernardi e Sonny Zampollo
Background
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumab may experience an increase in blood absolute eosinophil count (AEC). However, the onset and temporal pattern of dupilumab-induced blood eosinophilia (DIBE) have not been thoroughly investigated in real life.
Objective
To evaluate DIBE prevalence and temporal pattern in patients with CRSwNP, and to determine associations between DIBE and adverse events (AEs), patients’ clinical characteristics, and treatment outcomes.
Methods
This is a multicentric historical prospective observational study conducted across 14 Italian centers of the DUPIREAL network. DIBE onset and temporal pattern, clinical characteristics, CRSwNP outcomes, and AEs were analyzed. DIBE was defined as an AEC increased by 50% from baseline and at least >500 cells/mm3, or AEC >1500 cells/mm3.
Results
A total of 564 patients with CRSwNP were enrolled. Mean AEC peaked at 3 months and declined by 12 months. Among patients developing DIBE (48.2%), 3 distinct temporal patterns were identified based on onset and duration: early-onset temporary (group 1, 30.7% patients), early-onset persistent (group 2, 14.4% patients), and late-onset (group 3, 3.2% patients). Asthma prevalence (P < .001), use of asthma inhalers (P < .001), and previous oral corticosteroid use (P < .045) were greater in patients with DIBE (group 1-3) than in patients without DIBE (group 0). DIBE >1500 cells/mm3 was associated with a higher risk of developing mild AEs (P < 0.001). DIBE occurrence did not influence dupilumab outcomes in patients with CRSwNP.
Conclusions
Distinct DIBE patterns have been identified in patients with CRSwNP based on eosinophilia temporal trends. DIBE was mainly observed in patients with comorbid asthma and previous use of systemic steroids. The findings confirm that DIBE is a mostly transient and harmless phenomenon associated only with mild AEs.
{"title":"Dupilumab-Induced Blood Eosinophilia in Patients With Chronic Rhinosinusitis With Nasal Polyps: Temporal Trends and Correlation With Adverse Events","authors":"Eugenio De Corso PhD , Claudio Montuori MD , Ernesto Pasquini MD , Ignazio La Mantia PhD , Angelo Ghidini PhD , Carlotta Pipolo PhD , Massimiliano Garzaro MD , Giancarlo Ottaviano PhD , Veronica Seccia MD , Andrea Ciofalo MD , Sara Torretta MD , Elena Cantone PhD , Giulia Danè MD , Fabio Pagella MD , Daniela Lucidi MD , Gian Luca Fadda MD , Alice Mannocci PhD , Carlo Cavaliere PhD , Giulio Pagliuca PhD , Frank Rikki Mauritz Canevari MD , Riccardo Bernardi e Sonny Zampollo","doi":"10.1016/j.jaip.2025.10.032","DOIUrl":"10.1016/j.jaip.2025.10.032","url":null,"abstract":"<div><h3>Background</h3><div>Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumab may experience an increase in blood absolute eosinophil count (AEC). However, the onset and temporal pattern of dupilumab-induced blood eosinophilia (DIBE) have not been thoroughly investigated in real life.</div></div><div><h3>Objective</h3><div>To evaluate DIBE prevalence and temporal pattern in patients with CRSwNP, and to determine associations between DIBE and adverse events (AEs), patients’ clinical characteristics, and treatment outcomes.</div></div><div><h3>Methods</h3><div>This is a multicentric historical prospective observational study conducted across 14 Italian centers of the DUPIREAL network. DIBE onset and temporal pattern, clinical characteristics, CRSwNP outcomes, and AEs were analyzed. DIBE was defined as an AEC increased by 50% from baseline and at least >500 cells/mm<sup>3</sup>, or AEC >1500 cells/mm<sup>3</sup>.</div></div><div><h3>Results</h3><div>A total of 564 patients with CRSwNP were enrolled. Mean AEC peaked at 3 months and declined by 12 months. Among patients developing DIBE (48.2%), 3 distinct temporal patterns were identified based on onset and duration: early-onset temporary (group 1, 30.7% patients), early-onset persistent (group 2, 14.4% patients), and late-onset (group 3, 3.2% patients). Asthma prevalence (<em>P <</em> .001), use of asthma inhalers (<em>P <</em> .001), and previous oral corticosteroid use (<em>P <</em> .045) were greater in patients with DIBE (group 1-3) than in patients without DIBE (group 0). DIBE >1500 cells/mm<sup>3</sup> was associated with a higher risk of developing mild AEs (<em>P <</em> 0.001). DIBE occurrence did not influence dupilumab outcomes in patients with CRSwNP.</div></div><div><h3>Conclusions</h3><div>Distinct DIBE patterns have been identified in patients with CRSwNP based on eosinophilia temporal trends. DIBE was mainly observed in patients with comorbid asthma and previous use of systemic steroids. The findings confirm that DIBE is a mostly transient and harmless phenomenon associated only with mild AEs.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Pages 482-494.e13"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaip.2025.10.040
Joao Pedro Lopes MD , George N. Konstantinou MD, PhD, MSc, MC , Jennifer Roeder , Mary Jo Strobel , Juliet M. Ross PsyD , Wendy M. Book MD , Talaya McCright-Gill MS , Mirna Chehade MD, MPH
{"title":"Patient and caregiver perspectives on the use of elemental formula in eosinophilic gastrointestinal disease","authors":"Joao Pedro Lopes MD , George N. Konstantinou MD, PhD, MSc, MC , Jennifer Roeder , Mary Jo Strobel , Juliet M. Ross PsyD , Wendy M. Book MD , Talaya McCright-Gill MS , Mirna Chehade MD, MPH","doi":"10.1016/j.jaip.2025.10.040","DOIUrl":"10.1016/j.jaip.2025.10.040","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"14 2","pages":"Pages 521-523"},"PeriodicalIF":6.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号